Travere Therapeutics, Inc. (0001438533) (Filer) — SEC 8-K Filing
Travere Therapeutics
May 11, 2026

Channel-specific outreach playbooks for deal origination.
Comparison posts, methodology, and analysis from the Tentt team.
Monthly market reports on M&A and private equity activity.
Free calculators for M&A, lending, and deal analysis.
Origination in the Age of AI.
Thermo Fisher Scientific has completed its acquisition of Clario Holdings, Inc. from a shareholder group led by Nordic Capital, Novo Holdings A/S, Astorg Asset Management S A.R.L., Cinven Limited, and Partners Group Private Equity Limited, managed by Par.
The deal is reported as closed, with Thermo Fisher as the acquirer and Clario as the target in healthcare and healthcare IT.
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Travere Therapeutics
May 11, 2026
Pharvaris
May 11, 2026
Partner Therapeutics→Bizengri (bispecific antibody)
May 11, 2026
The Surgery Center of Southern Oregon
May 11, 2026
Mobia Medical
May 11, 2026